Loading...

Home
ETF
JANX

JANX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

JANX News

Janux Therapeutics and Bristol Myers Squibb Sign $800 Million Collaboration Agreement

Jan 22 2026Benzinga

Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for Tumor-Activated Therapy Development

Jan 22 2026stocktwits

Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for $50M Collaboration on Solid Tumor Therapy

Jan 22 2026NASDAQ.COM

Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million

Jan 22 2026seekingalpha

Janux Completes Phase 1a Trial for JANX008, Initiates Expansion Cohorts

Dec 24 2025NASDAQ.COM

Janux Initiates Expansion Phase for JANX008 Clinical Trial Targeting EGFR

Dec 23 2025Businesswire

Janux Executive Sells 16,665 Shares for $501,000 Through Options Exercise

Dec 04 2025NASDAQ.COM

Stifel Continues to Recommend Buy for Janux Therapeutics (JANX)

Dec 03 2025NASDAQ.COM

Gold Declines More Than 1%; Signet Stock Drops Following Q3 Earnings Report

Dec 02 2025Benzinga

Midday Stock Highlights: Maplebear, Boeing, Credo Technology, XPO, MongoDB, and Others

Dec 02 2025CNBC

Janux Therapeutics Shares Reach 52-Week Low Following Trial Announcement

Dec 02 2025Benzinga

Nasdaq Rises by 200 Points as United Natural Foods Reports Positive Earnings

Dec 02 2025Benzinga

Applied Materials Expected to Surge by 12%? Check Out 10 Leading Analyst Predictions for Tuesday

Dec 02 2025Benzinga

Signet Jewelers, Janux Therapeutics, BW LPG, and Other Major Stocks Decline in Tuesday's Pre-Market Trading

Dec 02 2025Benzinga

Janux Therapeutics Shares Plunge 41% Despite 'Positive' Results from Cancer Drug Trial.

Dec 02 2025Barron's

Premarket Stock Highlights: MongoDB, Strategy, Signet Jewelers, Credo, and Others Making Significant Moves

Dec 02 2025CNBC